Absorption and elimination of α-thrombin and tranexamic acid after fibrin sealant application on resected livers in rabbits

Blood Coagulation and Fibrinolysis

Volumn 9, Issue 6, 1998, Pages 533-537

  Nur, I ^a,d   Routledge, L ^b   Lushkov, G ^c   Paulmier, P ^a   Virat, M ^b  

^a Omrix Biopharmaceuticals SA   (Belgium)

^b Chrysalis Intl Preclinical Services   (France)

^c TEL AVIV UNIVERSITY   (Israel)

^d Omri Laboratories Ltd   (Israel)

Author keywords

Fibrin sealant; Fibrinogen; Pharmacokinetics; Tranexamic acid; thrombin

Indexed keywords

FIBRIN GLUE; THROMBIN; TRANEXAMIC ACID; TRICHLOROACETIC ACID;

ABDOMINAL SURGERY; ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOTTING; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; HEMOSTASIS; INTRAVENOUS DRUG ADMINISTRATION; LIVER RESECTION; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0031764447     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199809000-00011     Document Type: Article

References (31)

1. Bayfield MS, Spotnitz WD. Fibrin sealant in thoracic surgery. Pulmonary applications, including management of bronchopleural fistula. Chest Surg Clin N Am 1996; 3: 567-583.
2. Jackson MR, MacPhee MJ, Drohan WN, Alving BM. Fibrin sealant: current and potential clinical applications. Blood Coag Fibrinol 1996; 8: 737-746.
3. Kjaergard HK, Fairbrother JE. Controlled clinical studies of fibrin sealant in cardiothoracic surgery - a review. Eur J Cardiothorac Surg, 1996; 10: 727-733.
4. Martinowitz U, Schulman S, Horoszowski H, Heim M. Role of fibrin sealants in surgical procedures on patients. Clin Orthop 1996; 328: 65-75.
5. Spotnitz WD. Fibrin sealant in the United States: clinical use at the University of Virginia. Thromb Haemost 1995; 74: 482-485.
6. Brennan M. Fibrin glue. Blood 1991; 5: 240-244.
7. Vinazzer H. Fibrin Sealing: Physiologic and Biochemical Background. Facial Plastic Surgery 1985; 2: 291-295.
8. Sierra DH. Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications. J Biomater Appl 1993; 7: 309-352.
9. Takada A, Takada Y, Mori T, Sakaguchi S. Prevention of severe bleeding by tranexamic acid in a patient with disseminated intravascular coagulation. Thromb Res 1990; 58: 101-108.
10. Ueshima S, Okada K, Matsuo O. Stabilization of plasmin by lysine derivatives. Clin Chim Acta 1996; 245: 7-18.
11. Higazi A, Mayer M. Effects of penicillins and 6-aminohexanoic acid on the kinetics of human plasmin. Biochem J 1989; 260: 609-612.
12. Naski MC, Shafer JA. A kinetic model for the alpha-thrombin catalyzed conversion of the plasma levels of fibrinogen to fibrin in the presence of antithrombin III. J Biol Chem 1991; 266: 13003-13010.
13. Hornyak TJ, Bishop PD, Shafer JA. Alpha-thrombin-catalyzed activation of human platelet factor XIII: relationship between proteolysis and factor XIIIa activity. Biochemistry 1989; 28: 7326-7332.
14. Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J. The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 1989; 8: 3467-3475.
15. Fenton JW II, Bing DH. Thrombin active-site regions. Semin Thromb Hemost 1986; 12: 200-208.
16. Butkowski RJ, Elion J, Downing MR, Mann KG. Primary structure of human prethrombin 2 and alpha-thrombin. J Biol Chem 1977; 252: 4942-4957.
17. Jesty J. The kinetics of inhibition of alpha-thrombin in human plasma. J Biol Chem 1986; 261: 10313-10318.
18. Van Deerlin VM, Tollefsen DM. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans. J Biol Chem 1991; 266: 20223-20231.
19. White GL, Holmes DD. A comparison of ketamine and the combination ketamine-xylazine for effective surgical anesthesia in the rabbit. Lab Anim Sci 1976; 26: 804-806.
20. Sanford TD, Colby ED. Effect of xylazine and ketamine on blood pressure, heart rate and respiratory rate in rabbits. Lab Anim Sci 1980; 30: 519-523.
21. Pilbrant A, Schannong M, Vessman J. Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol 1981; 20: 65-72.
22. Puigdellvol E, Carral ME, Moreno J, Pla-Delfina JM, Jane F. Pharmacokinetics and absolute bioavailability of intramuscular tranexamic acid in man. Int J Clin Pharmacol Ther Toxicol 1985; 23: 298-301.
23. Almer S, Andersson T, Stram M. Pharmacokinetics of tranexamic acid in patients with ulcerative colitis and in healthy volunteers after the single instillation of 2g rectally. J Clin Pharmacol 1992; 32: 49-54.
24. Miura S, Mii Y, Miyauchi Y, Ohgushi H, Morishita T, Hohnoki K, et al. Efficacy of slow-releasing anticancer drug delivery systems on transplantable osteosarcomas in rats. Jpn J Clin Oncol 1995; 25: 61-71.
25. Pipan CM, Glasheen WP, Matthew TL, Gonias SL, Hwang L-J, Jane JA, et al. Effects of antifibrinolytic agents on the life span of fibrin sealant. J Surg Res 1992; 53: 402-407.
26. Boissel JP, Le Bonniec B, Rabiet MJ, Labie D, Elion J. Covalent structures of beta and gamma autolytic derivatives of human alpha-thrombin. J Biol Chem 1984; 259: 5691-5697.
27. Le Bonniec BF, Guinto ER, Esmon CT. Interaction of thrombin des-ETW with antithrombin III, the Kunitz inhibitors, thrombomodulin and protein C. Structural link between the autolysis loop and the Tyr-Pro-Pro-Trp insertion of thrombin. J Biol Chem 1992; 267: 19341-19348.
28. Bezeaud A, Guillin MC. Enzymic and nonenzymic properties of human beta-thrombin. J Biol Chem 1988; 263: 3576-3581.
29. Church FC, Pratt CW, Noyes CM, Kalayanamit T, Sherrill GB, Tobin RB, Meade JB. Structural and functional properties of human alpha-thrombin, phosphopyridoxylated alpha-thrombin, and gamma T-thrombin. Identification of lysyl residues in alpha-thrombin that are critical for heparin and fibrin(ogen) interactions. J Biol Chem 1989; 264: 18419-18425.
30. Braun PJ, Hofsteenge J, Chang JY, Stone SR. Preparation and characterization of proteolyzed forms of human alpha-thrombin. Thromb Res 1988; 50: 273-283.
31. Savion N, Isaacs JD, Gospodarowicz D, Shuman MA. Internalization and degradation of thrombin and up regulation of thrombin-binding sites in corneal endothelial cells. J Biol Chem 1981; 256: 4514-4519.